Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to accurately identify cancer spread.

Researchers at Brown University Health have identified a key molecular mechanism that may improve treatment for glioblastoma, one of the most aggressive forms of adult brain cancer. In a study published November 10 in Cell Reports, the team found that differences among cells within a single tumor play a major role in chemotherapy resistance and uncovered a small molecule, miR-181d, that helps regulate this variability. By stabilizing miR-181d levels, researchers were able to make tumor cells respond more uniformly to chemotherapy, potentially increasing its effectiveness. The discovery has already led to the development of a promising new gene-therapy–based approach aimed at improving outcomes for patients with glioblastoma.

Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African-American patients survive for half as long as their counterparts of European ancestry, according to a new review study led by researchers from the University of Maryland School of Medicine’s (UMSOM) Institute for Genome Sciences (IGS) and the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC).

Highlights

•

Marine ecosystems are rich in unique compounds such as alkaloids, peptides, polysaccharides, and terpenes with potent anticancer activities.

•

Marine-derived compounds exert their effects through multiple mechanisms, including apoptosis induction, cell cycle arrest, angiogenesis inhibition, and metastasis suppression.

•

Several marine compounds, like trabectedin and eribulin, have progressed to clinical use, showcasing the translational potential of marine-derived molecules in cancer therapy.

•

Despite promising results, challenges such as sustainable sourcing, structural complexity, and optimization for clinical application remain key hurdles in marine drug development.

Highlights

•

Genetic and epigenetic alterations, metabolic reprogramming, and survival mechanisms govern chemoresistance in cancer.

•

Cancer cells evade drug effects through metabolic reprogramming.

•

Resistance mechanisms are countered by tailored medicine and targeted medicines.

•

Combination regimens use a variety of strategies to overcome resistance

•

Novel treatment approaches to overcome resistance are guided by molecular understanding